Featured Content

  • Medivation’s Xtandi Threatened by J&J’s New Acquisition One of the biotech laggards of the year, Medivation (NASDAQ: MDVN) saw a very high volume selloff (-6.78% ▼$47.41/share) yesterday after rival Johnson & Johnson (NYSE: JNJ) announced the acquisition of Aragon Pharmaceuticals – a company that was developing a Phase II metastatic castration-resistant prostate cancer (mCRPC) drug that the market considers a threat to Xtandi - Medivation’s lone pipeline drug.
  • Biodel Primed To Capitalize On Next Generation Treatments In The $10B Diabetes Market Glucose is one of the most important chemical structures because it is essential in providing the body with energy. It is integral in the chemical process called aerobic respiration, which generates a usable form of energy. Glycolysis is the beginning of this process, which oxidizes glucose to form CO2, H20, and adenosine triphosphate (ATP).
  • Short Sellers Flee Questcor on Sentiment Reversal Questcor Pharmaceuticals (NASDAQ: QCOR) was one of the most heavily shorted stocks on the NASDAQ according to the most recent data set from May 31st 2013, with 22.15 M shares short out of a float of 53.6 M share (41%).
More News

Subscriber Only Content

More News

Sector News

More News


More Articles...
<< Start < Prev 1 3 4 5 6 7 8 9 10 > End >>

Page 1 of 799
BioMedReports Healthcare Review: ACADIA Pharmaceuticals, Chembio Diagnostics, STAAR Surgical, GenMark Diagnostics, Arena Pha... http://t.co/oQkwRxU8ce
15hreplyretweetfavorite
BioMedReports Medivation’s Xtandi Threatened by J&J’s New Acquisition: One of the biotech laggards of the year, Medivation (... http://t.co/VwmG4D0XY3
19hreplyretweetfavorite
navigation
Benzinga.com supporter Seeking Alpha Certified

RSS Subscription